Healius Limited (ASX:HLS)

Market Cap	370.33M -61.8%
Revenue (ttm)	1.37B +6.0%
Net Income	-168.80M
EPS	-0.23
Shares Out	726.13M
PE Ratio	n/a
Forward PE	44.74
Dividend	0.41 (80.98%)
Ex-Dividend Date	May 9, 2025

Volume	4,088,261
Average Volume	3,627,126
Open	0.5250
Previous Close	0.5200
Day's Range	0.5050 - 0.5300
52-Week Range	0.5050 - 1.6350
Beta	0.38
RSI	30.30
Earnings Date	Aug 9, 2026

About Healius

Healius Limited provides medical laboratory and pathology services in Australia. The company provides services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetnostics Pathology, QML Pathology, TML Pathology, Abbott Pathology, IQ Pathology, Kossard, Gastrolab, and Agilex Biolabs brands. It operates medical laboratories and patient collection centers. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1994
• Employees: 8,224
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: HLS

Financial Performance

In fiscal year 2025, Healius's revenue was 1.34 billion, an increase of 5.69% compared to the previous year's 1.27 billion. Losses were -151.20 million, -76.59% less than in 2024.